Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity
dc.contributor.author | Kraft, Shawna L. | en_US |
dc.contributor.author | Baker, Nicole M. | en_US |
dc.contributor.author | Carpenter, Julia | en_US |
dc.contributor.author | Bostwick, Jolene R. | en_US |
dc.date.accessioned | 2014-01-08T20:34:25Z | |
dc.date.available | 2015-03-02T14:35:34Z | en_US |
dc.date.issued | 2014-01 | en_US |
dc.identifier.citation | Kraft, Shawna L.; Baker, Nicole M.; Carpenter, Julia; Bostwick, Jolene R. (2014). "Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity." Psycho‐Oncology 23(1): 108-113. | en_US |
dc.identifier.issn | 1057-9249 | en_US |
dc.identifier.issn | 1099-1611 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102071 | |
dc.description.abstract | Background Procarbazine is an anticancer agent that also inhibits monoamine oxidase, an enzyme responsible for the metabolism of various catecholamines, including serotonin. Methods A retrospective chart review of lymphoma patients who were treated with both procarbazine and an antidepressant, as well as procarbazine alone, was performed to determine if signs and symptoms of serotonin toxicity were present. Results A total of 65 patients received procarbazine between 2004 and 2010 and were eligible to be included in the study. Twenty‐six of these patients received an antidepressant in combination with procarbazine, with selective serotonin reuptake inhibitors being the most common type of antidepressant. No patients in the study were diagnosed with serotonin toxicity, nor did any meet Hunter's diagnostic criteria for serotonin toxicity. Diarrhea, tremor, and shivering were the symptoms from Sternbach's criteria that were further analyzed, with diarrhea occurring 8.54% of the time, tremor occurring 5.53% of the time, and shivering occurring 2.51% of the time in patients who received an antidepressant with their procarbazine. Despite these symptoms, the diagnosis of serotonin toxicity according to Sternbach's criteria was determined to be unlikely. Conclusions In this small sample of patients treated with procarbazine plus an antidepressant (most typically SSRIs), there were no reports of serotonin toxicity, nor did any patients demonstrate symptoms consistent with serotonin toxicity. The authors urge clinicians to ensure depression is adequately managed in cancer patients who are undergoing procarbazine therapy, starting with typical first‐line antidepressant agents. Copyright © 2013 John Wiley & Sons, Ltd. | en_US |
dc.publisher | McGraw‐Hill | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Cancer | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Serotonin Toxicity | en_US |
dc.subject.other | Depression | en_US |
dc.subject.other | Antidepressant | en_US |
dc.subject.other | Procarbazine | en_US |
dc.title | Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102071/1/pon3378.pdf | |
dc.identifier.doi | 10.1002/pon.3378 | en_US |
dc.identifier.source | Psycho‐Oncology | en_US |
dc.identifier.citedreference | Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148 ( 6 ): 705 – 713. | en_US |
dc.identifier.citedreference | Holt A, Callingham BA. Further studies on the ex‐vivo effects of procarbazine and monomethylhydrazine on rat semicarbazide‐sensitive amine oxidase and monoamine oxidase activities. J Pharm Pharmacol 1995; 47: 837 – 845. | en_US |
dc.identifier.citedreference | Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Available at: http://www.micromedexsolutions.com/home/dispatch [Accessed December 19, 2012]. | en_US |
dc.identifier.citedreference | Lexi‐Comp Online, [Internet database] Hudson, Ohio: Lexi‐Comp, Inc. Available at: http://www.crlonline.com/lco/action/home/switch [Accessed December 19, 2012]. | en_US |
dc.identifier.citedreference | Facts & Comparisons. [Internet database] St. Louis, MO: Wolters Kluwer Health, Inc. Available at: http://online.factsandcomparisons.com [Accessed December 19, 2012]. | en_US |
dc.identifier.citedreference | Epocrates online. [Internet database] San Mateo, CA: Epocrates, Inc. Available at: https://online.epocrates.com/ [Accessed December 19, 2012]. | en_US |
dc.identifier.citedreference | Roper K, McDermott K, Cooley M, Daley K, Fawcett J. Health‐related quality of life in adults with Hodgkin's disease: the state of the science. Cancer Nurs 2009; 32: E1 – E17. | en_US |
dc.identifier.citedreference | Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve‐month DSM‐IV disorders in the National Comorbidity Survey Replication (NCS‐R). Arch Gen Psychiatry 2005; 62: 617 – 627. | en_US |
dc.identifier.citedreference | Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve month use of mental health services in the United States. Arch Gen Psychiatry 2005; 62: 629 – 640. | en_US |
dc.identifier.citedreference | Reich M. Depression and cancer: recent data on clinical issues, research challenges and treatment approaches. Curr Opin Oncol 2008; 20: 353 – 359. | en_US |
dc.identifier.citedreference | Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 ( Suppl E1 ): e04. | en_US |
dc.identifier.citedreference | American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition. 2010. Available at: http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485 [Accessed December 19, 2012]. | en_US |
dc.identifier.citedreference | Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine 2000; 79: 201 – 209. | en_US |
dc.identifier.citedreference | Bronstein AC, Spyker DA, Cantilena LR, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' national poison data system (NPDS): 29th annual report. Clin Toxicol (Phila) 2012; 50: 911 – 1164. | en_US |
dc.identifier.citedreference | Boyer EW. Serotonin syndrome. In UpToDate, Traub SJ, Grayzel J (eds), UpToDate: Waltham, MA, 2013. | en_US |
dc.identifier.citedreference | Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635 – 642. | en_US |
dc.identifier.citedreference | Isbister G, Buckley N, Whyte I. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007; 187: 361 – 365. | en_US |
dc.identifier.citedreference | van Eys J, Cangir A, Pack R, Baram T. Phase I trial of procarbazine as a 5‐day continuous infusion in children with central nervous system tumors. Cancer Treat Rep 1987; 71: 973 – 974. | en_US |
dc.identifier.citedreference | National Comprehensive Cancer Network. Central Nervous System Cancers (Version 2.2013). http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf [Accessed July 10, 2013]. | en_US |
dc.identifier.citedreference | National Comprehensive Cancer Network. Non‐Hodgkin's Lymphoma (Include Version 1.2013). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf [Accessed July 10, 2013]. | en_US |
dc.identifier.citedreference | Maxwell MB. Reexamining the dietary restrictions with procarbazine (an MAOI). Cancer Nurs 1980; 3: 451 – 457. | en_US |
dc.identifier.citedreference | Matulane ® [package insert]. Gaithersburg, MD; Sigma‐tau Pharmaceuticals, Inc.; 2008. | en_US |
dc.identifier.citedreference | Chu E, Sartorelli AC. Chapter 54. Cancer chemotherapy. In Basic & Clinical Pharmacology ( 12th edn ), Katzung BG, Masters SB, Trevor AJ (eds), McGraw‐Hill: New York, 2012. http://www.accesspharmacy.com/content.aspx?aID=55831105. [Accessed July 10, 2013]. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.